Home › NDC Lookup › Ingredients › Abiraterone Acetate › 00093-1125-89
⚪no package photo
in the FDA label

Abiraterone Acetate 250 mg Tablet, Film Coated, 120-count — NDC 0093-1125-89 (Billing 00093-1125-89)

by Teva Pharmaceuticals USA, Inc. · 120 TABLET, FILM COATED in 1 BOTTLE

This is a package of 120 tablets of Abiraterone Acetate 250 mg Tablet, Film Coated from Teva Pharmaceuticals USA, Inc., no longer marketed, no longer in the FDA NDC Directory; retail pharmacies pay about $0.8995 per tablet (NADAC). It is this product's only package size.

NDC 00093-1125-89
🏷️ FDA NDC (as labeled) 0093-1125-89 billing pads the labeler segment with a zero
Rx only Generic Discontinued Non-controlled ⚠ Discontinued by firm ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Mar 13, 2024 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0093-1125-89 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0093 labeler · 1125 product · 89 package
Billing quantity
120 EA per package
Barcode (UPC-A, from the NDC)
3 0093112589 7
FDA record last changed
Mar 13, 2024
⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Mar 2021. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0093-1125-89
Product NDC 0093-1125
11-digit billing NDC 00093112589
NCPDP billing unit EA — each (per item)
Application # ANDA208432
Mechanism of action Cytochrome P450 17A1 Inhibitor [EPC], Cytochrome P450 17A1 Inhibitors [MoA], Cytochrome P450 2C8 Inhibitors [MoA], Cytochrome P450 2D6 Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Mar 2021)
Route ORAL
Dosage form TABLET, FILM COATED
Substance ABIRATERONE ACETATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GCN Seq No 067349
GCN 29886
HICL code 037571
Ingredient (HICL) Abiraterone Acetate
HIC1 code V
Therapeutic class — broad (HIC1) Neoplasms
HIC2 code V1
Therapeutic class — intermediate (HIC2) Antineoplastic Drugs
HIC3 code V1J
Therapeutic class — specific (HIC3) Antineoplastic - Antiandrogenic Agents
AHFS code 10:00.00.00
AHFS class Antineoplastic Agents
FDB label name ABIRATERONE ACETATE 250 MG TAB
FDB brand name Abiraterone Acetate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 067349
  • GCN: 29886
  • HICL (First Databank): 037571
  • AHFS class code: 10:00.00.00
Why two NDCs? The FDA registers this code as 0093-1125-89 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00093-1125-89. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Label name ABIRATERONE ACETATE 250 MG TAB Ingredient Abiraterone Acetate
📖 What it is MedlinePlus · NLM

Abiraterone is used in combination with prednisone to treat a certain type of prostate cancer that has spread to other parts of the body. Abiraterone is in a class of medications called androgen biosynthesis inhibitors. It works by decreasing the amount of certain hormones in the body.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats prostate cancer that has spread. Abiraterone acetate tablets, Abirtega and Zytiga are used for metastatic castration-resistant and metastatic high-risk castration-sensiti...
  • Take it once a day and swallow the tablets whole with water. With abiraterone acetate tablets, Abirtega or Zytiga, don't eat for 2 hours before or 1 hour after your dose, because f...
  • How should I take it, and does food matter?
  • Abiraterone can cause a hormone imbalance, leading to high blood pressure, low potassium and fluid retention. The steroid is part of your treatment. Don't skip it or stop suddenly,...
📖 Read our full Abiraterone guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.900 $107.94 / 120 tablets
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
NADAC price history (per ea) — tap or hover for the price & month
Apr 2022 Sep 2022 Nov 2022 Feb 2024 $1.909 $0.900
▼ Down 53% over the last 7 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
00093-1125-89 You're viewing this Main listing 120 TABLET, FILM COATED in 1 BOTTLE 2018-11-21 — Discontinued by firm

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Abiraterone 250 mg 00143-9597-21 Hikma 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 00378-6920-78 Mylan 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 00904-6948-04 Major 30 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 16714-0963-01 NorthStar 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 43598-0358-04 Dr. 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 50268-0032-12 AvPAK 20 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 60219-1165-07 Amneal 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 60505-4327-01 Apotex 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 60687-0790-21 American 30 tablets $0.774 AB Availability likely save 14%
Abiraterone acetate 250 mg 64980-0418-12 Rising 120 tablets $0.774 AB Availability likely save 14%
Abiraterone 250 mg 68001-0489-07 BluePoint 120 tablets $0.774 AB Availability likely save 14%
abiraterone acetate 250 mg 68462-0135-08 Glenmark 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 69238-1165-07 Amneal 120 tablets $0.774 AB Availability likely save 14%
abiraterone acetate 250 mg 71921-0178-20 Florida 120 tablets $0.774 AB Availability likely save 14%
Abiraterone 250 mg 72205-0030-92 Novadoz 120 tablets $0.774 AB Availability likely save 14%
abiraterone acetate 250 mg 72603-0110-01 NORTHSTAR 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 75907-0224-04 Dr. 120 tablets $0.774 AB Availability likely save 14%
Abiraterone 250 mg 82009-0139-12 Quallent 120 tablets $0.774 AB Availability likely save 14%
Abiraterone 250 mg 82249-0010-12 CivicaScript, 120 tablets $0.774 AB Availability likely save 14%
Abirtega 250 mg 82249-0011-12 CivicaScript, 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mg 82293-0001-10 Novugen 120 tablets $0.774 AB Availability likely save 14%
Abiraterone Acetate 250 mgthis 00093-1125-89 Teva 120 tablets $0.899 — Discontinued —
Abiraterone Acetate 250 mg 42291-0024-12 AvKARE 120 tablets — AB FDA listed —
Zytiga 250 mg 57894-0150-12 Janssen 120 tablets — AB FDA listed —
Abiraterone 250 mg 72205-0284-05 Novadoz 500 tablets — AB FDA listed —
Abiraterone 250 mg 72789-0213-98 PD-Rx 120 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

📍
2026
Currently FDA-listed
listed with the FDA
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Abiraterone inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

We could not link this NDC to a current FDA Structured Product Label. An inactive-ingredient list is therefore not available from this source.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerTeva Pharmaceuticals USA, Inc.
Application holderTEVA PHARMACEUTICALS USA INC
FDA applicationANDA208432 (ANDA)
Labeler code00093
Product typeHuman Prescription Drug
Portfolio504 products on file

More NDCs from Teva Pharmaceuticals USA, Inc. labeler code 00093

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
📄 FDA label
📄 FDA label 19 words ▾

No FDA label is on file for this product yet. Labels load from openFDA / DailyMed and refresh weekly.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Abiraterone Acetate — the program that covers self-administered drugs. 14 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Abiraterone Acetate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$121.07M
Claims incl. refills
107.8K
Beneficiaries
43K
Spend / beneficiary
$2,817.78
Spend / claim
$1,123.43
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Abiraterone Acetate — the ingredient across all brands.

Top reported reactions

Death6,192
Fatigue2,680
Prostatic Specific Antigen Increased2,017
Therapy Cessation1,563
Hot Flush1,491
Asthenia1,317
Disease Progression1,221

Age at onset

Infant2
Child1
Adolescent1
Adult1,798
Elderly11,491

Reporter sex

0 reports

Serious outcomes

Death8,380
Life-threatening1,099
Disabling356
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 5,088 855
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

About this NDC listing & data coverage

Finished prescription product No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) — Not published for this NDC No structured label is linked to this listing in DailyMed/openFDA.
Package photos — Not published for this NDC The FDA label for this product carries no photos.
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no full label on this page?
No structured FDA label (SPL) is currently linked to this NDC in DailyMed/openFDA. That can happen with older listings, certain OTC and repackaged products, and recently updated listings whose label has not yet propagated. The listing itself is still valid — this page shows everything the public feeds provide for this package.
What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Who lists this product with the FDA?
Teva Pharmaceuticals USA, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00093-1122-01 · Teva 00093-1135-56 · Teva →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.